We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00216775
First Posted: September 22, 2005
Last Update Posted: September 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hiroyuki Marusawa, Kyoto University
September 10, 2005
September 22, 2005
September 2, 2015
December 2004
May 2008   (Final data collection date for primary outcome measure)
rate of sustained viral response [ Time Frame: 6 months ]
Not Provided
Complete list of historical versions of study NCT00216775 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C
Not Provided
The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
patients with chronic hepatitis C
Hepatitis C, Chronic
Drug: interferon-alfa-2b and ribavirin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
May 2008
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses

Exclusion Criteria:

  • Hemoglobin levels<8.5g/dL,
  • Platelet counts<50,000/mm3,
  • Total polymorphonuclear counts<1000/mm3
  • Pregnancy,
  • Renal dysfunction,
Sexes Eligible for Study: All
20 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00216775
H16-697
Not Provided
Not Provided
Not Provided
Hiroyuki Marusawa, Kyoto University
Kyoto University
Not Provided
Study Chair: Tsutomu Chiba, M.D., Ph.D Kyoto University
Kyoto University
September 2015